US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

3.83

+0.21005.80%

Post-market: 3.860.0300+0.78%18:19 EDT

Volume:868.61K

Turnover:3.24M

Market Cap:318.64M

PE:-2.96

High:3.85

Open:3.65

Low:3.59

Close:3.62

52wk High:5.81

52wk Low:1.22

Shares:83.20M

Float Shares:65.21M

Volume Ratio:0.99

T/O Rate:1.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2925

EPS(LYR):-0.8000

ROE:-4796.52%

ROA:-48.06%

PB:-24.54

PE(LYR):-4.79

Loading ...

Overview Company News Filings

Bremworth Secures IRD Clearance in Floorscape Acquisition Process

MT Newswires Live

Opus Genetics Inc. Announced Annual Stockholder Meeting

Opus Genetics Inc - Registers 7.4 Mln Shares of Common Stock for Resale Offered by Selling Stockholders - SEC Filing

THOMSON REUTERS

Opus Genetics files to sell 7.37M shares of common stock for holders

Opus Genetics Is Maintained at Outperform by Wedbush

Chardan Raises Price Target on Opus Genetics to $11 From $9, Keeps Buy Rating

MT Newswires Live

Opus Genetics (IRD) Gets a Buy from H.C. Wainwright

Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA)

Opus Genetics FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million

Press Release: Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Opus Genetics to Present at Leerink Global Healthcare Conference, Citizens Life Sciences Conference, and RBC Capital Markets Global Ophthalmology Conference

Opus Genetics Is Maintained at Buy by BTIG

H.C. Wainwright Sticks to Their Buy Rating for Opus Genetics (IRD)

Opus Genetics reports initial Phase 1/2 OPGx-BEST1 gene therapy data in BEST1 retinal disease

Opus Genetics Announces Initial Clinical Data From Phase 1/2 Opgx-Best1 Gene Therapy Study at the Macula Society Annual Meeting

THOMSON REUTERS

Buy Rating on IRD Driven by Low-Risk Presbyopia Launch and High-Potential BEST1 Gene Therapy Pipeline

FDA accepts Opus Genetics sNDA for phentolamine ophthalmic solution 0.75% to treat presbyopia

Opus Genetics Inc - FDA Sets Pdufa Date for October 17, 2026

THOMSON REUTERS

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IRD/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":3.83,"timestamp":1788292800000,"preClose":3.62,"halted":0,"volume":868612,"hourTrading":{"tag":"盘后","latestPrice":3.86,"preClose":3.83,"latestTime":"18:19 EDT","volume":6135,"amount":23339.36823,"timestamp":1788301166127,"change":0.03,"changeRate":0.007833,"amplitude":0.018277},"delay":0,"changeRate":0.0580110497237569,"floatShares":65209799,"shares":83195823,"eps":-1.292468,"marketStatus":"Post-Mkt","change":0.21,"latestTime":"09-01 19:08:02 EDT","open":3.65,"high":3.85,"low":3.59,"amount":3243053.237648,"amplitude":0.071823,"askPrice":4,"askSize":25,"bidPrice":3.76,"bidSize":46,"shortable":3,"etf":0,"ttmEps":-1.292468,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":3.62,"preHourTrading":{"tag":"盘前","latestPrice":3.6,"preClose":3.62,"latestTime":"09:03 EDT","volume":21264,"amount":77493.08415360001,"timestamp":1788267790759,"change":-0.02,"changeRate":-0.005525,"amplitude":0.135359},"postHourTrading":{"tag":"盘后","latestPrice":3.86,"preClose":3.83,"latestTime":"18:19 EDT","volume":6135,"amount":23339.36823,"timestamp":1788301166127,"change":0.03,"changeRate":0.007833,"amplitude":0.018277},"volumeRatio":0.994947,"optionData":{"bulkOrders":[{"symbol":"IRD","call":true,"expireDate":1789704000000,"strike":"5.0","timestamp":1788282080470,"price":0.3,"volume":2000,"amount":60000,"type":"+"},{"symbol":"IRD","call":true,"expireDate":1789704000000,"strike":"7.5","timestamp":1788282080470,"price":0.05,"volume":2000,"amount":10000,"type":"-"}]},"impliedVol":3.104,"impliedVolPercentile":0.877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":65209799,"roa":"-48.06%","roe":"-4796.52%","lyrEps":-0.8,"volumeRatio":0.994947,"shares":83195823,"dividePrice":0,"high":3.85,"amplitude":0.071823,"preClose":3.62,"low":3.59,"week52Low":1.22,"pbRate":"-24.54","psRate":"32.33","week52High":5.81,"institutionHeld":0,"latestPrice":3.83,"committee":0.295775,"eps":-1.292468,"divideRate":0,"volume":868612,"delay":0,"ttmEps":-1.292468,"open":3.65,"prevYearClose":2.01,"prevWeekClose":3.69,"prevMonthClose":3.62,"prevQuarterClose":4.11,"fiveDayClose":4.11,"twentyDayClose":3.71,"sixtyDayClose":4.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"IRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2026-05-12","symbol":"IRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2026-03-10","symbol":"IRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.11,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2632,"buy":0.7368,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7368,"analysts":19,"updateTime":1785384000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-08-31","current":-2.963323,"percent":0.244541,"low":-8.249622,"twenty":-2.987922,"median":-2.001473,"eighty":-1.130382,"high":-0.560128,"avg":-2.382162,"sd":1.791947,"marketCap":306992586},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-13","current":-3.427836,"twenty":-2.136977,"median":-1.323479,"eighty":-1.031375,"marketCap":233788665},{"date":"2026-02-20","current":-3.609844,"twenty":-2.149226,"median":-1.323479,"eighty":-1.038117,"marketCap":246202222},{"date":"2026-02-27","current":-3.630068,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"marketCap":247581506},{"date":"2026-03-06","current":-4.823238,"twenty":-2.163754,"median":-1.335088,"eighty":-1.055298,"marketCap":328959272},{"date":"2026-03-13","current":-6.821589,"twenty":-2.163832,"median":-1.335088,"eighty":-1.05838,"marketCap":338289413},{"date":"2026-03-20","current":-6.571003,"twenty":-2.174573,"median":-1.340893,"eighty":-1.062543,"marketCap":325862626},{"date":"2026-03-27","current":-6.48492,"twenty":-2.196211,"median":-1.358307,"eighty":-1.072721,"marketCap":321593683},{"date":"2026-04-02","current":-6.728822,"twenty":-2.279157,"median":-1.369917,"eighty":-1.078827,"marketCap":333689021},{"date":"2026-04-10","current":-7.890943,"twenty":-2.31549,"median":-1.383164,"eighty":-1.078974,"marketCap":391319747},{"date":"2026-04-17","current":-8.249622,"twenty":-2.347317,"median":-1.393136,"eighty":-1.079587,"marketCap":409107008},{"date":"2026-04-24","current":-7.474875,"twenty":-2.424764,"median":-1.39894,"eighty":-1.079843,"marketCap":370686524},{"date":"2026-05-01","current":-7.357517,"twenty":-2.49456,"median":-1.404745,"eighty":-1.081468,"marketCap":364866631},{"date":"2026-05-08","current":-7.717474,"twenty":-2.527902,"median":-1.450845,"eighty":-1.086096,"marketCap":382717249},{"date":"2026-05-15","current":-3.318654,"twenty":-2.605325,"median":-1.471353,"eighty":-1.089005,"marketCap":354870285},{"date":"2026-05-22","current":-2.864592,"twenty":-2.625631,"median":-1.50381,"eighty":-1.089833,"marketCap":306316604},{"date":"2026-05-29","current":-2.804496,"twenty":-2.764432,"median":-1.520037,"eighty":-1.093147,"marketCap":299890382},{"date":"2026-06-05","current":-3.098301,"twenty":-2.804496,"median":-1.567278,"eighty":-1.099183,"marketCap":331307470},{"date":"2026-06-12","current":-2.976252,"twenty":-2.841362,"median":-1.641006,"eighty":-1.10936,"marketCap":318256557},{"date":"2026-06-18","current":-3.09043,"twenty":-2.862186,"median":-1.648544,"eighty":-1.10936,"marketCap":330465888},{"date":"2026-06-26","current":-2.831626,"twenty":-2.921273,"median":-1.671763,"eighty":-1.117502,"marketCap":302791405},{"date":"2026-07-02","current":-3.181773,"twenty":-2.964753,"median":-1.703207,"eighty":-1.119538,"marketCap":340233353},{"date":"2026-07-10","current":-3.103979,"twenty":-3.005472,"median":-1.779688,"eighty":-1.123486,"marketCap":331914656},{"date":"2026-07-17","current":-2.5326,"twenty":-2.998741,"median":-1.85001,"eighty":-1.127372,"marketCap":270815938},{"date":"2026-07-24","current":-2.254631,"twenty":-2.977774,"median":-1.874663,"eighty":-1.129113,"marketCap":241092238},{"date":"2026-07-31","current":-2.964995,"twenty":-2.973207,"median":-1.900983,"eighty":-1.129716,"marketCap":317052806},{"date":"2026-08-07","current":-2.854241,"twenty":-2.967182,"median":-1.931317,"eighty":-1.129716,"marketCap":307144906},{"date":"2026-08-14","current":-2.87602,"twenty":-2.967182,"median":-1.947379,"eighty":-1.129716,"marketCap":309488461},{"date":"2026-08-21","current":-3.185269,"twenty":-2.973207,"median":-1.951541,"eighty":-1.129716,"marketCap":342766790},{"date":"2026-08-28","current":-2.976526,"twenty":-2.991855,"median":-1.986619,"eighty":-1.13016,"marketCap":320303918},{"date":"2026-08-31","current":-2.852826,"twenty":-2.987922,"median":-2.001473,"eighty":-1.130382,"marketCap":306992586}],"updateTime":1788301321246},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622050016","title":"Bremworth Secures IRD Clearance in Floorscape Acquisition Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2622050016","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622050016?lang=en_us&edition=fundamental","pubTime":"2026-03-25 06:09","pubTimestamp":1774390188,"startTime":"0","endTime":"0","summary":"Bremworth  has received a binding New Zealand tax ruling from the Inland Revenue Department  on its proposed capital return, clearing a key step in Floorscape's planned acquisition of all the company shares, according to a Wednesday filing with the New Zealand bourse.The ruling satisfies a key condition under the scheme implementation agreement, but the scheme remains subject to other requirements, including clearance from the New Zealand Commerce Commission, approval by the company shareholders, and final high court approval, per the filing.The company said shareholders do not need to take any action at this stage, as reported in the filing.The company's shares fell around 2% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IRD.AU","BK7129","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081213","title":"Opus Genetics Inc. Announced Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081213?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:08","pubTimestamp":1774296507,"startTime":"0","endTime":"0","summary":"Opus Genetics will hold its annual stockholders meeting virtually on April 20, 2026.Shareholders will vote on the election of nine director nominees to the board.Items for advisory votes include the ratification of Ernst & Young as independent public accounting firm and approval of named executive officer compensation.Another proposal seeks approval of an amendment to increase authorized common shares to 250,000,000 from 125,000,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL3FL714:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619714384","title":"Opus Genetics Inc - Registers 7.4 Mln Shares of Common Stock for Resale Offered by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2619714384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619714384?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:02","pubTimestamp":1773435727,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4011CO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619439151","title":"Opus Genetics files to sell 7.37M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2619439151","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619439151?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:00","pubTimestamp":1773435632,"startTime":"0","endTime":"0","summary":"16:57 EDT Opus Genetics (IRD) files to sell 7.37M shares of common stock for holders Published first on TheFly – the ultimate source for real-time,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-files-to-sell-7-37m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-files-to-sell-7-37m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134738","title":"Opus Genetics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134738","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134738?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:33","pubTimestamp":1773318780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 12, 2026 08:33 ET (12:33 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618135352","title":"Chardan Raises Price Target on Opus Genetics to $11 From $9, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135352","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618135352?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:43","pubTimestamp":1773312205,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) has an average rating of buy and mean price target of $9.45, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","IRD","BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618946645","title":"Opus Genetics (IRD) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618946645?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:37","pubTimestamp":1773225446,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Opus Genetics, with a price target of $8.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/opus-genetics-ird-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/opus-genetics-ird-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618968909","title":"Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618968909?lang=en_us&edition=fundamental","pubTime":"2026-03-11 01:50","pubTimestamp":1773165009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and ImageneBio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-opus-genetics-ird-imagenebio-ima-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-opus-genetics-ird-imagenebio-ima-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","IRD","LABU","BK4588","BLSX","IMA","BK4137","BLSG","BK4585","XBI","BK4139","BK4007","LU0128526141.USD","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618934455","title":"Opus Genetics FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934455","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934455?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:06","pubTimestamp":1773140760,"startTime":"0","endTime":"0","summary":"Opus Genetics reported a FY 2025 net loss of USD 49.6 million, compared with a FY 2024 net loss of USD 57.5 million. FY 2025 license and collaborations revenue rose 29% to USD 14.2 million, driven by its Viatris collaboration for reimbursement of R&D services. FY 2025 R&D expenses increased 15% to USD 30.8 million due to higher clinical research, toxicology, payroll and professional services costs, partly offset by lower manufacturing and regulatory costs. FY 2025 G&A expenses rose 21% to USD 22 million on higher legal and patent-related, payroll, public-company and professional services costs. Opus Genetics ended FY 2025 with USD 45.1 million in cash and cash equivalents and said it expects aggregate cash resources of USD 70.1 million, including a USD 25 million private placement completed after year-end, to fund operations into the first half of 2028.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL90B92F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4583","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","BK4585","SG9999014039.USD","BK4139","IE00B3QW5Z07.USD","SG9999014013.SGD","NDAQ","BK4588","LU1839511570.USD","VTRS","LU0314104364.USD","IE00BGHQF748.EUR","LU2087621335.USD","SG9999014021.USD","IRD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618993439","title":"Press Release: Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618993439","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618993439?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:00","pubTimestamp":1773140400,"startTime":"0","endTime":"0","summary":"- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -. - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher  program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -. - FDA Prescription Drug User Fee Act  date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -. \"We are delivering a steady cadence of data and milestones across our pipeline,\" said George Magrath, M.D., Chief Executive Officer, Opus Genetics. \"With positive clinical results from both our BEST1 and LCA5 gene therapy programs, new funding for our MERTK program and an upcoming FDA PDUFA date for Phentolamine Ophthalmic Solution 0.75% in presbyopia, we are advancing therapies with both scientific promise and compelling commercial potential. The reauthorization of the U.S. Rare Pediatric Disease Priority Review Vo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CST","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616334027","title":"Opus Genetics to Present at Leerink Global Healthcare Conference, Citizens Life Sciences Conference, and RBC Capital Markets Global Ophthalmology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334027","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616334027?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:01","pubTimestamp":1772542895,"startTime":"0","endTime":"0","summary":"Opus Genetics to Present at Leerink Global Healthcare Conference, Citizens Life Sciences Conference, and RBC Capital Markets Global Ophthalmology Conference","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL6yMGCv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","IRD","BK4588","SG9999014013.SGD","BK4007","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616343233","title":"Opus Genetics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2616343233","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616343233?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:28","pubTimestamp":1772454480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 07:28 ET (12:28 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616367113","title":"H.C. Wainwright Sticks to Their Buy Rating for Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616367113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616367113?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:38","pubTimestamp":1772451497,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Opus Genetics, with a price target of $8.00. Caufield ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614857184","title":"Opus Genetics reports initial Phase 1/2 OPGx-BEST1 gene therapy data in BEST1 retinal disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614857184?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:10","pubTimestamp":1772205015,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. reported initial clinical data from its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy for BEST1 mutation-associated retinal diseases, based on three-month results from the first  adult participant presented at the Macula Society Annual Meeting. The company said the treatment was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities, and reported a 12-letter gain in best corrected visual acuity and a 23% reduction in central subfield thickness in the treated eye at three months. Opus Genetics stated that full Cohort 1 three-month results are expected to be presented in mid-year 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDLgmwfF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","IRD","LU2210150020.SGD","BK4588","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","NDAQ","BK4007","LU2095319765.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614644857","title":"Opus Genetics Announces Initial Clinical Data From Phase 1/2 Opgx-Best1 Gene Therapy Study at the Macula Society Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2614644857","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614644857?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:10","pubTimestamp":1772205000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA8CJPSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614034497","title":"Buy Rating on IRD Driven by Low-Risk Presbyopia Launch and High-Potential BEST1 Gene Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614034497","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614034497?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:45","pubTimestamp":1772037947,"startTime":"0","endTime":"0","summary":"Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy rating ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-ird-driven-by-low-risk-presbyopia-launch-and-high-potential-best1-gene-therapy-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-ird-driven-by-low-risk-presbyopia-launch-and-high-potential-best1-gene-therapy-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614899120","title":"FDA accepts Opus Genetics sNDA for phentolamine ophthalmic solution 0.75% to treat presbyopia","url":"https://stock-news.laohu8.com/highlight/detail?id=2614899120","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614899120?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:59","pubTimestamp":1772020761,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. said the U.S. Food and Drug Administration has accepted for review its supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat presbyopia. The agency set a PDUFA goal date of Oct. 17, 2026. The product, marketed as Ryzumvi, is currently approved in the U.S. for reversal of pharmacologically induced mydriasis, and the filing seeks to expand its indication; Viatris holds exclusive U.S. commercialization rights under a licensing agreement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL9FdXLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SG9999014013.SGD","BK4583","SG9999014021.USD","BK4585","SG9999014005.SGD","BK4112","LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","BK4139","LU2210149790.SGD","VTRS","LU1839511570.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU2087621335.USD","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614089659","title":"Opus Genetics Inc - FDA Sets Pdufa Date for October 17, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089659?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:59","pubTimestamp":1772020740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUAZBPFM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614089633","title":"Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089633?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:59","pubTimestamp":1772020740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUAZBPFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":119,"code":"91000000","status":"200"}]}}